vs
Bioceres Crop Solutions Corp.（BIOX）与REGIS CORP（RGS）财务数据对比。点击上方公司名可切换其他公司
Bioceres Crop Solutions Corp.的季度营收约是REGIS CORP的1.4倍（$77.6M vs $57.1M），REGIS CORP净利率更高（0.8% vs -9.6%，领先10.4%），REGIS CORP同比增速更快（22.3% vs -16.8%），过去两年REGIS CORP的营收复合增速更高（7.8% vs -8.4%）
Bioceres Crop Solutions Corp是一家全球农业科技企业，研发并商业化耐旱种子性状、生物肥料、生物农药等可持续作物增产解决方案，服务南美、北美、欧洲及亚太地区的农户，致力于提升作物产量，同时降低农业生产的环境影响。
瑞吉斯公司是一家美国美发沙龙运营商，总部位于明尼苏达州明尼阿波利斯市。截至2021年8月，该集团旗下拥有5563家加盟沙龙以及276家直营门店，是北美地区规模领先的美发沙龙连锁经营企业。
BIOX vs RGS — 直观对比
营收规模更大
BIOX
是对方的1.4倍
$57.1M
营收增速更快
RGS
高出39.1%
-16.8%
净利率更高
RGS
高出10.4%
-9.6%
两年增速更快
RGS
近两年复合增速
-8.4%
损益表 — Q1 FY2026 vs Q2 FY2026
| 指标 | | |
|---|---|---|
| 营收 | $77.6M | $57.1M |
| 净利润 | $-7.4M | $456.0K |
| 毛利率 | 46.8% | — |
| 营业利润率 | 9.3% | 10.8% |
| 净利率 | -9.6% | 0.8% |
| 营收同比 | -16.8% | 22.3% |
| 净利润同比 | -20.2% | -94.0% |
| 每股收益（稀释后） | $-0.12 | $0.16 |
绿色 = 该指标领先。财年不对齐时期间可能不同
8季度营收与利润趋势
并排季度历史对比，按日历期对齐，财年错位的公司也能正确匹配
营收BIOXRGS
| Q4 25 | — | $57.1M | ||
| Q3 25 | $77.6M | $59.0M | ||
| Q2 25 | — | $60.4M | ||
| Q1 25 | $60.6M | $57.0M | ||
| Q4 24 | $98.8M | $46.7M | ||
| Q3 24 | $93.3M | $46.1M | ||
| Q2 24 | — | $49.4M | ||
| Q1 24 | $84.0M | $49.2M |
净利润BIOXRGS
| Q4 25 | — | $456.0K | ||
| Q3 25 | $-7.4M | $1.4M | ||
| Q2 25 | — | $116.5M | ||
| Q1 25 | $-1.6M | $250.0K | ||
| Q4 24 | $605.2K | $7.6M | ||
| Q3 24 | $-6.2M | $-853.0K | ||
| Q2 24 | — | $91.2M | ||
| Q1 24 | $9.8M | $-2.3M |
毛利率BIOXRGS
| Q4 25 | — | — | ||
| Q3 25 | 46.8% | — | ||
| Q2 25 | — | — | ||
| Q1 25 | 39.4% | — | ||
| Q4 24 | 42.0% | — | ||
| Q3 24 | 40.2% | — | ||
| Q2 24 | — | — | ||
| Q1 24 | 50.8% | — |
营业利润率BIOXRGS
| Q4 25 | — | 10.8% | ||
| Q3 25 | 9.3% | 10.0% | ||
| Q2 25 | — | 12.1% | ||
| Q1 25 | 1.5% | 8.8% | ||
| Q4 24 | 14.5% | 11.8% | ||
| Q3 24 | 2.5% | 4.6% | ||
| Q2 24 | — | — | ||
| Q1 24 | 15.7% | 8.3% |
净利率BIOXRGS
| Q4 25 | — | 0.8% | ||
| Q3 25 | -9.6% | 2.3% | ||
| Q2 25 | — | 192.9% | ||
| Q1 25 | -2.6% | 0.4% | ||
| Q4 24 | 0.6% | 16.4% | ||
| Q3 24 | -6.6% | -1.9% | ||
| Q2 24 | — | 184.7% | ||
| Q1 24 | 11.6% | -4.7% |
每股收益（稀释后）BIOXRGS
| Q4 25 | — | $0.16 | ||
| Q3 25 | $-0.12 | $0.49 | ||
| Q2 25 | — | $43.67 | ||
| Q1 25 | $-0.02 | $0.08 | ||
| Q4 24 | $0.00 | $2.71 | ||
| Q3 24 | $-0.10 | $-0.36 | ||
| Q2 24 | — | $38.40 | ||
| Q1 24 | $0.14 | $-1.00 |
资产负债表与财务实力
最新季度各公司的流动性、杠杆与账面价值一览
| 指标 | | |
|---|---|---|
| 现金及短期投资手头流动性 | $15.5M | $18.4M |
| 总债务越低越好 | — | $113.3M |
| 股东权益账面价值 | $288.3M | $188.7M |
| 总资产 | $734.9M | $588.3M |
| 负债/权益比越低杠杆越低 | — | 0.60× |
8季度趋势，按日历期对齐
现金及短期投资BIOXRGS
| Q4 25 | — | $18.4M | ||
| Q3 25 | $15.5M | $16.6M | ||
| Q2 25 | — | $17.0M | ||
| Q1 25 | $38.5M | $13.3M | ||
| Q4 24 | $29.2M | $10.2M | ||
| Q3 24 | $32.3M | $6.3M | ||
| Q2 24 | — | $10.1M | ||
| Q1 24 | $16.4M | $5.9M |
总债务BIOXRGS
| Q4 25 | — | $113.3M | ||
| Q3 25 | — | $111.3M | ||
| Q2 25 | — | $110.8M | ||
| Q1 25 | — | $112.0M | ||
| Q4 24 | — | $111.5M | ||
| Q3 24 | — | $95.2M | ||
| Q2 24 | — | $99.5M | ||
| Q1 24 | — | $179.7M |
股东权益BIOXRGS
| Q4 25 | — | $188.7M | ||
| Q3 25 | $288.3M | $187.6M | ||
| Q2 25 | — | $185.6M | ||
| Q1 25 | $345.0M | $68.6M | ||
| Q4 24 | $346.3M | $66.7M | ||
| Q3 24 | $346.0M | $56.4M | ||
| Q2 24 | — | $56.8M | ||
| Q1 24 | $348.5M | $-35.8M |
总资产BIOXRGS
| Q4 25 | — | $588.3M | ||
| Q3 25 | $734.9M | $592.1M | ||
| Q2 25 | — | $599.0M | ||
| Q1 25 | $798.2M | $511.2M | ||
| Q4 24 | $835.2M | $530.1M | ||
| Q3 24 | $827.3M | $508.9M | ||
| Q2 24 | — | $530.5M | ||
| Q1 24 | $836.1M | $543.7M |
负债/权益比BIOXRGS
| Q4 25 | — | 0.60× | ||
| Q3 25 | — | 0.59× | ||
| Q2 25 | — | 0.60× | ||
| Q1 25 | — | 1.63× | ||
| Q4 24 | — | 1.67× | ||
| Q3 24 | — | 1.69× | ||
| Q2 24 | — | 1.75× | ||
| Q1 24 | — | — |
现金流与资本效率
扣除再投资后实际产生的现金。现金流比净利润更难造假
| 指标 | | |
|---|---|---|
| 经营现金流最新季度 | $14.4M | $1.7M |
| 自由现金流经营现金流 - 资本支出 | — | $891.0K |
| 自由现金流率自由现金流/营收 | — | 1.6% |
| 资本支出强度资本支出/营收 | — | 1.4% |
| 现金转化率经营现金流/净利润 | — | 3.65× |
| 过去12个月自由现金流最近4个季度 | — | $14.9M |
8季度趋势，按日历期对齐
经营现金流BIOXRGS
| Q4 25 | — | $1.7M | ||
| Q3 25 | $14.4M | $2.3M | ||
| Q2 25 | — | $6.8M | ||
| Q1 25 | $23.3M | $6.2M | ||
| Q4 24 | $-5.4M | $2.1M | ||
| Q3 24 | $5.2M | $-1.3M | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | $-17.4M | $-277.0K |
自由现金流BIOXRGS
| Q4 25 | — | $891.0K | ||
| Q3 25 | — | $1.9M | ||
| Q2 25 | — | $6.2M | ||
| Q1 25 | — | $5.9M | ||
| Q4 24 | — | $1.7M | ||
| Q3 24 | — | $-1.4M | ||
| Q2 24 | — | $5.1M | ||
| Q1 24 | — | $-326.0K |
自由现金流率BIOXRGS
| Q4 25 | — | 1.6% | ||
| Q3 25 | — | 3.2% | ||
| Q2 25 | — | 10.3% | ||
| Q1 25 | — | 10.3% | ||
| Q4 24 | — | 3.6% | ||
| Q3 24 | — | -3.0% | ||
| Q2 24 | — | 10.3% | ||
| Q1 24 | — | -0.7% |
资本支出强度BIOXRGS
| Q4 25 | — | 1.4% | ||
| Q3 25 | — | 0.7% | ||
| Q2 25 | — | 0.9% | ||
| Q1 25 | — | 0.6% | ||
| Q4 24 | — | 0.9% | ||
| Q3 24 | — | 0.0% | ||
| Q2 24 | — | 0.0% | ||
| Q1 24 | — | 0.1% |
现金转化率BIOXRGS
| Q4 25 | — | 3.65× | ||
| Q3 25 | — | 1.68× | ||
| Q2 25 | — | 0.06× | ||
| Q1 25 | — | 24.80× | ||
| Q4 24 | -8.85× | 0.28× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 0.06× | ||
| Q1 24 | -1.78× | — |
财务流量对比
营收 → 毛利润 → 营业利润 → 净利润流向图
业务分部营收拆解
BIOX
暂无分部数据
RGS
| Franchise Segment | $37.9M | 66% |
| Royalty | $13.6M | 24% |
| Other | $2.8M | 5% |
| Fees | $1.8M | 3% |
| Franchise Fees | $1.0M | 2% |
